https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19267
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19267
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADGlecaprevir / Pibrentasvir can decrease the P-gp and increase the plasma concentration of Digoxin.
–
–
–
Possible increase of adverse effects.
Use this combination with caution.
Therapeutic concentration monitoring of is recommended before initiating and during glecaprevir/pibrentasvir therapy.
Product monograph suggests to decrease the dose by approximately 50% or modify the dosing frequency and continue monitoring.
–
Adverse effects of digoxin: Gastrointestinal effects (abdominal discomfort, nausea/vomiting, diarrhea, anorexia, dyspepsia), central nervous system effects, vision disorders, fatigue, headache, bradycardia and rhythm disorders.
Digoxinemia
| Reference number |
|---|
| # patients |
| HCV |
| Dose |
| Frequency |
| Cmax |
| AUC |
| 3373 |
|---|
| 12 |
| - |
| 400/120 mg |
| QD |
| 3373 |
|---|
| 12 |
| - |
| 0.5 mg |
| x 1 |
| + 72% |
| + 48% |
Ref #3373 : No significant changes in glecaprevir or pibrentasvir concentrations.